For all of history, humans treated disease with "pills" — small molecules. But over the last 40 years we've climbed a whole ladder: from pills, to biologics grown from living cells, to injecting cells and genes that repair the body, all the way up to RNA that tells the body to make its own medicine. This node is the map that threads the 16 categories of Biotech into one picture — how each "way of making a drug" differs, who feeds whom, and why the weight-loss wave is shaking the entire industry (each category has its own deep-dive chapter).
Biotech surges on deals, gene therapy wins, and wider GLP-1 coverage
▲
Record M&A and IPO activity June saw a wave of biotech mergers and public listings, led by AbbVie's purchase of Apogee and Merck KGaA's deal for Bio-Techne, signaling strong investor appetite and confidence in the sector.
This is a major new force driving sector momentum and capital flows.
▲
Gene therapy breakthroughs UniQure reported promising Huntington's data, Intellia advanced its CRISPR therapy to phase 3, and Ionis won FDA approval, marking significant clinical and regulatory progress for genetic medicines.
These are new technological and regulatory wins that boost the sector's growth outlook.
▲
Expanded Medicare GLP-1 coverage Medicare widened coverage for GLP-1 obesity drugs, opening a vast new market for treatments that address a major public health need and promising substantial revenue growth for manufacturers.
This is a new regulatory and demand catalyst with broad market impact.
▼
Legal and trade risks weigh on sector Fraud, patent, and safety lawsuits hit GRAIL, Erasca, and ADMA, while Eli Lilly halved its German investment and a US Section 301 probe into German drug rebates threatens tariffs, adding uncertainty.
These are new negative developments that could undermine trust and increase costs.
Latest
▲3▼1
Obesity drugs surge, cancer wins pile up, CAR-T safety scare
▲
Obesity drugs hit new highs Lilly's oral pill Foundayo cut heart risk in a huge diabetes trial and grabbed a third of new oral GLP-1 patients; Lilly's retatrutide helped patients lose about 21% of body weight. Novo's CagriSema beat Lilly's tirzepatide in a head-to-head trial, and Novo licensed a Chinese obesity drug for up to $2.6 billion. The obesity demand engine keeps getting stronger.
Shows the biggest commercial force in biotech right now: obesity and diabetes drugs, with multiple new wins.
▲
Cancer drug wins and big deals Bristol Myers' ZENBEXUS doubled MRD-negative responses in myeloma; Merck/Eisai's WELIREG combo and Lilly's Jaypirca won FDA approvals; Roche's giredestrant cut breast cancer progression risk 44%. AstraZeneca invested $2 billion in Summit Therapeutics for cancer combos, and Dizal got a $600 million upfront from AstraZeneca. This shows steady new products and strong dealmaking in oncology.
Oncology is a core sub-area; these approvals and deals show the theme's innovation and capital flow.
▼
CAR-T safety scare deepens Novartis paused eight CAR-T trials in autoimmune and neurological diseases after three patient deaths from a severe immune reaction; Bristol Myers paused enrollment in its competing CAR-T program. This is a real setback for cell therapy, reminding investors that these treatments carry high safety risks and can slow development.
A major safety event that directly hits the cell therapy sub-area and investor confidence.
▲
RNA and immunology deals broaden Abogen licensed an mRNA T-cell engager to Novartis in a deal worth up to $7.2 billion, and Sanofi paid Regeneron $1 billion upfront to expand their antibody alliance. Takeda's psoriasis drug beat a rival, and Pfizer's vitiligo drug hit Phase 3 goals. These deals and data wins validate RNA and immunology as growing areas.
Shows new capital and clinical validation in RNA and immunology, two key sub-areas of the theme.
Q3 2026
▲2▼2
Gene editing, obesity drugs, and mRNA drive biotech higher
▲
Gene editing and mRNA clinical wins Vertex's Casgevy won FDA approval for toddlers, Intellia's in-vivo gene-editing Phase 3 succeeded, and Moderna-Merck's mRNA cancer vaccine cleared Phase 3, marking major advances for genetic medicines.
These are the biggest new clinical and regulatory breakthroughs this quarter.
▲
Obesity drug boom and Lilly's trillion-dollar milestone Lilly's GLP-1 revenue surged and it became the first $1 trillion pharma, while the first AI-designed drug entered Phase 3, showing how obesity and AI are reshaping biotech.
Captures the financial and technological forces driving the sector.
▼
Clinical and regulatory setbacks AstraZeneca/Ionis heart-trial failures, a gene-editing trial death in China, Capricor's FDA rejection, and failures at Sionna, EyePoint, BioNTech, and Novartis weighed on sentiment.
Shows the real counterweight to the positive news.
▼
Policy and legal pressures US generic tariffs, the GRAIL lawsuit, Most Favored Nation pricing, and AstraZeneca-BMS antitrust uncertainty added pressure, while REGENXBIO's FDA hold and CAR-T safety scares paused trials.
Highlights ongoing regulatory and trade risks affecting the sector.
News & notes movingBiotech & Genomic Medicine
United States
Rare Disease2
Capricor Falls 10% as Deramiocel OLE Data Fails to Ease FDA Concerns
Capricor Therapeutics shares fell about 10% in Monday trading despite positive data from an open-label extension study of deramiocel for Duchenne muscular dystrophy, as investors remained doubtful the candidate will win US FDA approval. A 24-month crossover analysis of HOPE-3 found that patients who began deramiocel after 12 months on placebo slowed upper limb decline by 76% compared to the first year, while patients always on deramiocel showed a similar reduction in rate of decline at both 12 and 24 months. H.C. Wainwright's Joseph Pantginis, who rates Capricor at neutral, said he expects a Complete Response Letter from the FDA for deramiocel, writing that the OLE data strengthens the efficacy story but does not resolve the regulatory uncertainty tied to what occurred during the randomized portion of HOPE-3. Cantor Fitzgerald's Kristen Kluska, who rates Capricor at overweight, was more optimistic, saying the 24-month OLE data reinforce the durability and consistency of the treatment effect and that she leans more toward a potential approval with an attractive risk/reward setup of plus 300% to minus 70%. The OLE analysis was included in a major amendment to the company's BLA, and deramiocel faces a Nov. 22 FDA action date after a late July FDA advisory panel failed to endorse the candidate following briefing documents from agency scientists that called HOPE-3 data into question.
Biotech & Genomic Medicine › Rare Disease Regulation
CAPR · Regulation · Negative Deramiocel OLE data fails to resolve FDA regulatory uncertainty ahead of the Nov. 22 action date, with analysts expecting a Complete Response Letter.
AstraZeneca Opens $1 Billion Kendall Square R&D Center in Cambridge, Massachusetts
AstraZeneca has opened its newest global strategic research and development center in Kendall Square, Cambridge, Massachusetts, part of a more than $1 billion investment in the state that will expand its Massachusetts workforce by over 50 percent in the coming years. The 570,000 square foot, 18 story site at 290 Binney Street will house nearly 2,000 researchers and scientists alongside the company's genomic medicine site at 100 Binney Street, and includes ten floors of interconnecting laboratories integrating robotics, continuous automation and agentic AI. The scientists will work on AstraZeneca's oncology, cell therapy, chronic disease and rare disease pipeline, targeting conditions such as COPD, obesity and metabolic disease, breast cancer and rare diseases, while pursuing future innovation in cell therapy and biologics to fuel growth beyond 2030. The Massachusetts investment sits within AstraZeneca's broader $50 billion US investment, and the new site joins its other US-based global strategic research center in Gaithersburg, Maryland, as part of a coast-to-coast footprint of 24 R&D, manufacturing, commercial and corporate sites. Chief Executive Officer Pascal Soriot said Kendall Square is a leading innovation ecosystem and one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs, while Massachusetts Governor Maura Healey called the investment a major vote of confidence in the state.
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint Capital
AZN.LSE · Capital · Positive AstraZeneca opens a $1B+ Kendall Square R&D center, part of its broader $50B US investment, expanding its Massachusetts workforce by over 50%.
Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
Novartis entered a licensing and option agreement with China-based Abogen Biosciences, giving the Swiss pharma giant exclusive worldwide rights to Abogen's lead candidate ABO2203 and options to license additional programs built on Abogen's proprietary RNA platform. Under the agreement, Abogen will receive an upfront payment of $575 million and is eligible to receive up to approximately $7.2 billion in potential milestone payments if all options covering additional programs are exercised and the specified development, regulatory and commercial milestones are achieved, plus royalties on future product sales. ABO2203 is an investigational messenger RNA-encoded CD19xCD3 T-cell engager being developed for autoimmune diseases, designed to reset B cells by directing endogenous production of T-cell engagers in vivo. The transaction remains subject to customary closing conditions, including required regulatory clearances. The deal comes as Novartis faces generic competition for Entresto and Promacta and back-to-back pipeline setbacks, including the late-stage failure of pelacarsen and the HARBOR study of del-desiran in myotonic dystrophy type 1.
Biotech & Genomic Medicine › RNA Therapeutics ▲Capital
Biotech & Genomic Medicine › mRNA Platforms ▲Capital
NOVN.SW · Capital · Positive Novartis signs $7.8B licensing/option deal with Abogen for RNA therapeutics, adding pipeline assets amid generic competition and pipeline setbacks
Abogen Biosciences · Capital · Positive Abogen receives $575M upfront and up to ~$7.2B in milestones plus royalties under the Novartis licensing and option agreement
Insmed CFO Sara Bonstein to Step Down October 30; Shares Fall 8%
Insmed Inc announced that Chief Financial Officer Sara Bonstein will step down on October 30, sending shares down 8% Monday. Bonstein will continue as CFO through the company's reporting of its third-quarter 2026 financial results and will participate in the earnings call on October 29, while Insmed has begun a search for her successor. She served as CFO for nearly seven years, during which Insmed raised more than $4.2 billion in capital, and the company said her transition is not related to any disagreement over accounting practices, financial statements, internal controls, or operations. Chair and Chief Executive Officer Will Lewis said Insmed is well positioned to reach cash flow positivity next year with a clear path toward sustained top-line growth and bottom-line profitability. The company reaffirmed its full-year 2026 guidance of revenue in the range of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE, and will release third-quarter 2026 results on October 29.
Vaxcyte Surges 32% on Positive Phase 3 Data for VAX-31 Pneumonia Vaccine
Vaxcyte shares jumped about 32% in Monday morning trading after the company reported positive phase 3 topline data for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The OPUS-1 trial tested non-inferiority and immunogenicity of VAX-31 against Merck's Capvaxive and Pfizer's Prevnar 20 in patients aged 50 and over. For the 11 serotypes shared by the three shots, VAX-31 met all primary noninferiority assessments, and three serotypes unique to VAX-31 plus cross-reactive serotype 20B met the OPA GMR superiority criterion. Vaxcyte plans to release results from two other phase 3 trials, OPUS-2 and OPUS-3, in the first half of 2027, with a BLA eyed for the first half of 2028. Approved vaccines cover significantly fewer pneumonia strains than VAX-31: Capvaxive covers 21 strains and Prevnar 20 covers 20.
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▲Competition
PCVX · Technology · Positive Positive phase 3 topline data for VAX-31 met non-inferiority and superiority criteria, advancing its lead vaccine candidate.
MRK · Competition · Negative Vaxcyte's VAX-31 beat Merck's Capvaxive on shared serotypes and covers more strains, a competitive threat to Capvaxive.
PFE · Competition · Negative VAX-31 matched Pfizer's Prevnar 20 on shared serotypes while covering more strains, a competitive threat to Prevnar 20.
Tempus AI Wins FDA Clearance for Two AI-ECG Cardiac Products
Tempus AI has received 510(k) clearance from the Food and Drug Administration for two next-generation AI cardiovascular products, Tempus ECG-MR and Tempus ECG-PH. Tempus ECG-MR analyzes standard 12-lead resting electrocardiograms to detect signs associated with undiagnosed moderate or severe mitral regurgitation, while Tempus ECG-PH is an AI-enabled software device that analyzes standard 12-lead ECG data and provides a binary output for signs associated with pulmonary hypertension. The clearances come as the AI-ECG analysis market is expected to grow from $2.01 billion in 2025 to $2.40 billion in 2026, a compound annual growth rate of 19.3%, according to the Business Research report. Among peers, GE HealthCare's Advanced Imaging Solutions segment, which combines the former Imaging and AVS businesses, generated $3.77 billion in revenues in the second quarter of 2026, up 5.0% organically, with segment EBIT margin rising 90 basis points to 13.9%. iRhythm Holdings, whose platform is supported by more than 3 billion hours of curated ECG data and more than 12 million patient reports, expanded work with Desert Oasis Healthcare and signed two commercial agreements through Luum during the second quarter of 2026. Tempus shares have declined 17.7% over the past year, and the stock currently trades at a forward 12-month price-to-sales ratio of 7.30X versus an industry average of 4.82X.
EpiSign and Geneyx Partner to Integrate Genomic and Epigenomic Rare-Disease Analysis
EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to advance the integration of genomic and epigenomic analysis for rare-disease interpretation. Under the collaboration, EpiSign METRIC becomes available to Geneyx customers, letting laboratories incorporate epigenomic evidence alongside genomic and phenotypic information in an integrated interpretation workflow. EpiSign METRIC automates analysis of disease-associated DNA methylation episignatures across more than 300 EpiSign-associated conditions, while EpiSign METRIC 5-base extends that capability beyond methylation microarrays to methylation data generated by Illumina 5-base, PacBio HiFi and Oxford Nanopore sequencing. Geneyx Chief Executive Officer David Yizhar said the partnership combines Geneyx's genomic and multi-omics analysis platform with EpiSign's expertise in DNA methylation and episignatures, and EpiSign co-founder and Chief Scientific Officer Dr. Bekim Sadikovic said genome sequencing increasingly generates genetic and epigenetic information from the same assay. EpiSign Chief Executive Officer Dan Sinai said generating genomic and epigenomic information together from a single assay can reduce wet-lab testing and data-generation costs and shorten the diagnostic odyssey for patients and families. EpiSign METRIC 5-base is available for research use only.
Summit Therapeutics, AstraZeneca and Daiichi Sankyo to Study Ivonescimab Plus Datroway Combos
Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
4568.JP · Technology · Positive Daiichi Sankyo's Datroway (datopotamab deruxtecan) will be evaluated in combination with ivonescimab across multiple solid tumors, including a phase III triple-negative breast cancer study
AZN.LSE · Technology · Positive AstraZeneca will co-sponsor and supply its Datroway ADC in a new phase III combination study with ivonescimab, expanding its oncology pipeline
CellCarta and Waters Form Strategic Partnership for Companion Diagnostics
CellCarta has established a strategic partnership with Waters Corporation to jointly pursue companion diagnostic and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs, aiming to give sponsors a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. Waters will provide underlying technology capabilities including instrumentation, reagents, standardized panels, assay development, software analysis, and where appropriate custom reagent and IVD commercialization, while CellCarta will integrate and deploy assays across its global CDx Lab Network, supporting Phase I-III clinical trial testing, analytical and clinical evidence generation, regulatory and logistics support, and commercial laboratory services. The companies cited existing platform alignment between CellCarta's CAP-accredited laboratory in Jining, China and BD flow cytometry platforms as a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs. Todd Chermak, President of CellCarta, said the partnership offers sponsors a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization, and that the companies are already engaging pharmaceutical and biotechnology companies on near-term opportunities.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Technology
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Technology
Biotech & Genomic Medicine › Life-Science Tools & Sequencing ▲Technology
WAT · Demand · Positive Waters forms strategic partnership with CellCarta to pursue companion diagnostic and next-gen flow cytometry opportunities with pharma/biotech sponsors.
CellCarta · Demand · Positive CellCarta partners with Waters to jointly pursue CDx and flow cytometry programs, integrating assays across its global CDx Lab Network for sponsors.
Novo Nordisk Targets Over $23 Billion in Pipeline Sales by 2035 as GLP-1 Competition Bites
Novo Nordisk is diversifying beyond its GLP-1 obesity and diabetes franchise, aiming to launch more than five potential blockbuster drugs by 2030 and generate over $23 billion in pipeline-related sales by 2035. The company, whose Ozempic and Wegovy have driven recent growth, has begun exploring the hair-loss market, which its Chief Scientific Officer says can leverage Novo's scientific knowledge, and plans to advance multiple Phase 3 programs across obesity, diabetes and other therapeutic areas. Chief Executive Mike Doustdar acknowledged the loss of confidence, saying it takes time and hard work to build back, after the company's post-Wegovy strategy presentation sent hair-loss drug developers Veradermics and Absci higher. Novo has lost ground to rival Lilly in the injectable GLP-1 market and faces key semaglutide patent expirations in major markets in the early 2030s, prompting Morgan Stanley to downgrade the stock to Sell on medium-term growth concerns. Novo trades at around 10.2x forward GAAP earnings, below its five-year average of 30.0x and the sector median of 23.3x, while its forward price-to-sales ratio of 3.8x is below its five-year average of 9.6x and broadly in line with the sector median of 3.7x.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
Aging Population › Chronic-Disease Pharma Franchises ▼Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies ▼Competition
NVO · Competition · Negative Novo Nordisk has lost ground to rival Lilly in the injectable GLP-1 market and faces semaglutide patent expirations, prompting a Morgan Stanley downgrade.
LLY · Competition · Positive Novo Nordisk acknowledged losing ground to rival Lilly in the injectable GLP-1 market, a competitive gain for Lilly.
ABSI · Demand · Positive Absci shares rose after Novo Nordisk's strategy presentation highlighted the hair-loss market, signaling potential demand for hair-loss drug developers.
MANE · Demand · Positive Veradermics shares rose after Novo Nordisk's strategy presentation signaled interest in the hair-loss market, a potential demand driver for hair-loss drug developers.
FDA Expands Eli Lilly's Jaypirca to First-Line CLL/SLL Treatment
Eli Lilly announced that the FDA has expanded the label of its oral cancer drug Jaypirca, also known as pirtobrutinib, to include a new indication in chronic lymphocytic leukemia or small lymphocytic lymphoma. Jaypirca has been approved to treat adults with previously untreated CLL/SLL who do not have a known 17p deletion, allowing the drug to be used as a first-line treatment for eligible patients. The approval is supported by data from the phase III BRUIN CLL-313 study, which showed that Jaypirca reduced the risk of disease progression or death by 80% compared to chemoimmunotherapy. Before this latest approval, Jaypirca was already approved for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor, and for adults with relapsed or refractory mantle cell lymphoma following two lines of systemic therapy including a BTK inhibitor. Jaypirca is already generating meaningful sales for Lilly, with revenues rising 66% year over year to $357 million in the first half of 2026, though its sales remain relatively small compared with Lilly's much larger obesity and diabetes portfolio.
AFT and Natera Launch AFT-70 NAVIGATE Phase III Trial of Giredestrant With Signatera MRD-Guided Therapy
Alliance Foundation Trials and Natera announced the launch of AFT-70 NAVIGATE, a global randomized phase III trial evaluating an MRD-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group. It pairs giredestrant, Genentech's investigational next-generation oral selective estrogen receptor degrader, with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from escalation with a CDK4/6 inhibitor. AFT expects to enroll more than 2,000 patients with stage II-III disease at approximately 200 sites across the U.S. and internationally, with the primary endpoint of non-inferiority in 4-year distant recurrence-free survival. Giredestrant was selected based on the phase III lidERA trial, which showed a statistically significant and clinically meaningful improvement in invasive disease-free survival versus standard endocrine monotherapy, while Signatera was chosen for its evidence in this setting and its Genome-based technology reporting analytical sensitivity below 1 ppm.
Biotech & Genomic Medicine › Oncology Therapeutics Technology
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Technology
Alliance Foundation Trials, LLC · Demand · Positive AFT is sponsoring and leading the AFT-70 NAVIGATE phase III trial, a major trial launch for the organization.
NTRA · Demand · Positive Natera's Signatera Genome MRD test is being used in the AFT-70 NAVIGATE phase III trial, expanding clinical adoption of its product.
Genentech, Inc. · Technology · Positive Genentech's investigational giredestrant is the trial's study drug, advancing its clinical development in early breast cancer.
ROP.SW · Technology · Positive Roche's Genentech unit is co-funding and collaborating on the trial of its investigational giredestrant paired with Signatera MRD monitoring.
Shionogi to Acquire IntraBio for USD 2.0 Billion, Adding AQNEURSA to Rare Disease Portfolio
Shionogi & Co., Ltd. announced that its Board of Directors approved an agreement to acquire IntraBio Inc., a biopharmaceutical company developing and commercializing therapies for neurodegenerative diseases, for an upfront consideration of USD 2.0 billion payable to IntraBio shareholders. Under the agreement signed on October 5, 2026, IntraBio would become a wholly owned subsidiary of New Jersey-based Shionogi Inc., with the transaction scheduled to close between November 2026 and December 2026, subject to competition-law waiting periods and other customary conditions. The deal would add AQNEURSA (levacetylleucine) to Shionogi's rare disease portfolio; the drug was approved by the FDA in September 2024 for neurological manifestations of Niemann-Pick disease type C and by the European Medicines Agency in January 2026, and on September 18, 2026 it became the first and only FDA-approved treatment for Ataxia in patients with Ataxia-Telangiectasia, for which it is also under EMA review. Shionogi said the acquisition builds on the rare disease foundation it established through its April 2026 acquisition of global rights to edaravone, known as RADICAVA in the U.S. and RADICUT in Japan, and would strengthen its pipeline across Pompe disease, Fragile X syndrome, Jordan's syndrome and early-stage rare neurodegenerative programs. The impact on Shionogi's consolidated financial results for the fiscal year ending March 2027 is currently under review.
Biotech & Genomic Medicine › Rare Disease ▲Capital
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▲Capital
4507.JP · Capital · Positive Shionogi's board approved a USD 2.0 billion acquisition of IntraBio, adding AQNEURSA and rare-disease pipeline assets to its portfolio.
IntraBio Inc. · Capital · Positive IntraBio is being acquired by Shionogi for USD 2.0 billion upfront, delivering consideration to its shareholders.
AstraZeneca Closes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics announced the closing of AstraZeneca's $2.0 billion strategic equity investment in the company. Under the Securities Purchase Agreement, AstraZeneca purchased approximately 108,955 shares of preferred stock convertible into Summit common stock at a 1:1,000 ratio, representing a common stock price of $18.36, a premium over the closing trading price on the day the investment was announced. The proceeds will support accelerated development of ivonescimab, a potential first-in-class investigational PD-1 / VEGF bispecific antibody, across solid tumor settings including combinations with antibody drug conjugates such as sonesitatug vedotin and Datroway. Summit Chairman and Co-Chief Executive Officer Robert W. Duggan said the investment reflects AstraZeneca's confidence in Summit and in ivonescimab's potential to redefine cancer treatment. Baker Hostetler LLP is serving as legal advisor to Summit.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Capital
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Capital
AZN.LSE · Capital · Positive AstraZeneca closed a $2.0 billion strategic equity investment in Summit Therapeutics, a major financing/M&A event for AstraZeneca.
SAFE targets 50,000 families under care, aims for 10-15% revenue growth in 2027
Safe Fertility Group Public Company Limited, or SAFE, has announced a three-to-five-year plan to expand its family care base from 40,000 families to 50,000 families, while driving average revenue growth of 10-15% per year from 2027 onward, after revenue in 2026 is expected to hold steady from the 900 million baht recorded in 2025. Dr. Wiwat Kwangkananurak, Chief Executive Officer, said the growth strategy comes from the Preserve and Prevent markets, as younger generations increasingly turn to egg freezing, sperm freezing, and genetic testing, as well as from expanding the base of international patients, who currently account for 50% of all patients. The company is also broadening its business scope into genetic analysis laboratories under Next Generation Genomic Company Limited, providing reproductive medicine and maternal and child medicine analysis services to leading public and private healthcare providers, as well as obstetrics and gynecology clinics both domestically and overseas. It is also in discussions on cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, with services under the NHSO project expected to begin in 2027. It is also discussing ways to provide intrauterine insemination, or IUI, for holders of universal health coverage rights, or the 30-baht scheme, to broaden access to treatment more comprehensively.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
SAFE.BK · Demand · Positive SAFE plans to expand its family care base from 40,000 to 50,000 families and grow revenue 10-15% yearly from 2027, driven by egg/sperm freezing, genetic testing, and international patients.
Moberg Pharma Publishes New Analyses on Terbinafine Susceptibility and MOB-015 in Journal of Fungi
Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis, with mycological cure achieved with MOB-015 across the full range of baseline terbinafine susceptibility, including in patients with reduced in vitro susceptibility. The analyses are based on data from the previously completed North American Phase 3 study evaluating daily treatment with MOB-015 for 48 weeks, and included 506 dermatophyte isolates from onychomycosis patients. Only 3.2% of baseline isolates showed elevated MIC values of at least 0.5 micrograms per milliliter, and among MOB-015-treated patients with evaluable end-of-study results, 74.3% achieved mycological cure, including two of three patients with elevated baseline MIC values. The work was conducted in collaboration with Professor Mahmoud Ghannoum at Case Western Reserve University in Cleveland, Ohio, and the article, titled In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial, is published in Journal of Fungi, 2026, 12(10), 739. Amir Tavakkol, CSO of Moberg Pharma, said the results are encouraging, particularly given the increasing attention to antifungal resistance, and that the findings further strengthen the scientific foundation for MOB-015.
Biotech & Genomic Medicine › Antiviral & Infectious-Disease Therapeutics ▲Technology
Moberg Pharma AB · Technology · Positive Publication of analyses showing potent terbinafine activity and MOB-015 mycological cure strengthens the scientific foundation for its lead product.
CSL Strikes $1.55B Lixudebart Deal With Alentis for Rare Kidney and Liver Diseases
CSL and Alentis Therapeutics have entered an exclusive global partnership to co-develop and co-promote lixudebart for rare kidney, liver, and other diseases. Under the agreement, CSL will arrange an initial payment of $355M to Alentis, which is also eligible for up to $1.2B in commercial milestone payments, bringing the total deal value to $1.55B. The companies will share global profits 55% to CSL and 45% to Alentis once the drug is commercialized. CSL will fund Phase 2 and planned Phase 3 studies of lixudebart in AAV-RPGN while advancing Phase 2 programs in FSGS and PSC. Lixudebart is currently being evaluated in the Phase 2 RENAL trial for AAV-RPGN, a rare autoimmune disease that can cause rapid kidney function loss and irreversible kidney damage.
Aroa Biosurgery Limited announced positive results from a prospective, multicenter randomized controlled trial of Symphony, published in the International Wound Journal. The study enrolled 143 patients across 10 U.S. sites and found that 55% of diabetic foot ulcers achieved complete wound closure within 12 weeks when Symphony was added to standard of care, compared with 35% receiving standard of care alone, a result with a p-value of 0.039. Mean time to complete wound closure was reduced by 7.8 days, to 65.4 days with Symphony plus standard of care versus 73.2 days with standard of care alone, a result with a p-value of 0.041. The trial enrolled patients with challenging Wagner Grade 1 or 2 diabetic foot ulcers, and patients were randomly assigned to receive weekly Symphony plus standard of care or standard of care alone for up to 12 weeks or until complete wound closure. Lead investigator Dr David Armstrong said the trial demonstrates that combining a novel extracellular matrix bioscaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to good standard of care. AROA CEO Brian Ward called the results a major milestone for Symphony and said the publication places Symphony among a small group of CAMPs with Level I effectiveness data, strengthening its differentiation and commercial value proposition.
AnnJi Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for SBMA
AnnJi Pharmaceutical announced it is proceeding with the U.S. portion of its pivotal Phase 3 ROMA-KD trial of AJ201, also known as rosolutamide, in patients with spinal and bulbar muscular atrophy, or SBMA, also called Kennedy's disease. The company said it submitted the Phase 3 protocol to the U.S. FDA under its active Investigational New Drug application and will now activate U.S. sites for the global trial. The ROMA-KD study is a global, multicenter, randomized, double-blind, placebo-controlled trial expected to enroll approximately 200 ambulatory patients with symptomatic SBMA worldwide, with the United States as a key region, and is intended to support potential global regulatory submissions. AJ201, an investigational oral small molecule and a potential first-in-class treatment for SBMA, has received Fast Track Designation from the U.S. FDA and Orphan Drug Designation in both the United States and the European Union. AnnJi said the Phase 3 program builds on encouraging results from its completed Phase 2 study announced in May 2025, and the company also noted its SBMA Patient and Care Partner Advisory Council, first announced in collaboration with the Kennedy's Disease Association at the 2026 KDA International Patient and Scientific Conference.
Neogen Set to Report Earnings Tuesday After Last Quarter's Revenue Beat
Neogen will report its latest quarterly earnings this Tuesday after market hours, with Wall Street expecting revenue to be flat year on year. The life sciences company beat analysts' revenue expectations last quarter, posting revenues of $225.3 million, flat year on year, and also topped analysts' EPS estimates while its full-year revenue guidance exceeded expectations. The flat revenue expected this quarter would mark an improvement from the 3.6% decrease Neogen recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, though Neogen has missed Wall Street's revenue estimates multiple times over the last two years. Neogen is the first among its peers to report earnings this season, and its shares are up 3.4% over the last month while the broader healthcare equipment and supplies segment has been flat.
Arcus Biosciences to Present New Casdatifan ARC-20 Kidney Cancer Data
Arcus Biosciences announced it will host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. The data package spans TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a pharmacodynamic correlations with overall survival. Arcus also plans to complete enrollment in the PEAK-1 Phase 3 trial and start PEAK-20 by year end 2026, with the ARC-20 datasets feeding into how credible those registrational bets look. The company's narrative projects $290.3 million revenue and $50.1 million earnings by 2029, yielding a $39.91 fair value and a 63% upside to its current price, while some of the lowest ranked analysts assume revenue could fall to about US$120.2 million by 2028.
Jim Cramer Says GRAIL Could Rise Like Moderna After FDA Panel Backs Galleri
Jim Cramer said GRAIL, Inc. could climb much higher after an FDA advisory panel backed its Galleri multi-cancer early detection test, comparing the stock to Moderna when it traded around $120. The panel voted 7-2 with one abstention that Galleri's benefits outweighed its risks, 6-4 on effectiveness and unanimously on safety, though the recommendation is not binding and final approval had not been granted as of October 2, with Reuters reporting a decision is expected in the coming months. GRAIL generated $44.7 million of revenue in the second quarter, up 26% year over year, as Galleri revenue rose 24% to $42.6 million and test volume increased 35% to more than 61,000, while the company posted a $110.2 million net loss and a $90.3 million adjusted EBITDA loss with $861.6 million in cash, cash equivalents and short-term marketable securities at June 30. Moderna, Inc. reported $145 million of revenue in the second quarter against $142 million a year earlier and a $782 million net loss, ending June with $6.9 billion in cash, cash equivalents and investments, and its Phase 3 INTerpath-001 trial of intismeran autogene with Merck's Keytruda met its recurrence-free-survival and distant-metastasis-free-survival endpoints in resected melanoma. Citi analyst Geoff Meacham said on September 30 that Moderna's roughly $80 billion market capitalization was approaching Regeneron's despite materially lower expected revenue and earnings, while GRAIL's bear case rests on adoption and reimbursement, with Galleri costing about $700 out of pocket and generally not covered by Medicare or private insurers.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Regulation
GRAL · Regulation · Positive FDA advisory panel voted 7-2 that Galleri's benefits outweigh risks, advancing it toward approval.
MRNA · Capital · Neutral Cramer compared GRAIL to Moderna at $120, while Citi noted Moderna's ~$80B market cap approaches Regeneron's despite lower expected revenue and earnings.
Vor Biopharma's Telitacicept Shows Durable Responses in Phase 3 Myasthenia Gravis Analysis
Vor Biopharma reported a post hoc analysis from a China-based Phase 3 trial showing that telitacicept produced deep, durable clinical responses and was generally well tolerated over 48 weeks in adults with generalized myasthenia gravis. The analysis highlighted that most patients who reached minimal symptom expression maintained it and spent much of their remaining follow-up in this state. The new data reinforce the depth and durability of response but do not materially change the key near-term catalyst, the UPSTREAM global Phase 3 topline readout in 2027, or the central risk that global data might not match prior China experience. The results sit beside Vor's completion of enrollment in the global UPSTREAM Phase 3 gMG trial in early September 2026. Vor Biopharma's narrative projects $111.0 million revenue and $19.1 million earnings by 2029, implying an earnings decrease of $608.7 million from $627.8 million today, and forecasts a $39.00 fair value, a 109% upside to its current price.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Technology
VOR · Technology · Positive Post hoc Phase 3 analysis shows telitacicept produced deep, durable responses over 48 weeks in generalized myasthenia gravis, reinforcing the drug's clinical profile.
Alligator Bioscience Names CFO Johan Giléus as CEO, Søren Bregenholt to Step Down at Year-End
Alligator Bioscience has appointed Johan Giléus, currently CFO, as its new Chief Executive Officer effective 1 January 2027, with Søren Bregenholt remaining CEO until 31 December 2026 to ensure a seamless transition. Giléus will combine the CEO and CFO roles, reflecting the company's strategic refocusing towards its financial interest in the HER2-targeting antibody programme HLX22, as announced on 23 July 2026. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants. Chairman Hans-Peter Ostler thanked Bregenholt for five years of leadership through a demanding period for the biotech sector, noting that the outcome with mitazalimab did not meet expectations, and said Giléus knows Alligator and its financial interest in HLX22 in depth. Giléus has more than 30 years of senior experience, including the last nine years in the Swedish biotech industry, and joined Alligator as CFO in August 2024 after leaving Deloitte Sweden's partnership in 2015. Alligator, listed on Nasdaq Stockholm under ATORX and headquartered in Lund, Sweden, has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Capital
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▼Capital
Alligator Bioscience AB · Capital · Negative CEO transition to a minimal organisation after discontinuing mitazalimab development and refocusing on the HLX22 financial interest signals a strategic retreat
Sanofi, Novartis and Novo Nordisk Lead Week of Multi-Billion-Dollar Healthcare Deals
A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.
Iovance Biotherapeutics Fair Value Raised to US$12.80 on Amtagvi Demand
The fair value estimate for Iovance Biotherapeutics has been raised to US$12.80 per share from US$10.00, according to Simply Wall St. The revision reflects stronger expectations for the Amtagvi launch, margin trends and upcoming data, with the revenue growth assumption shifting from 43.38% to 45.57% and the net profit margin assumption moving from 9.50% to 12.09%. H.C. Wainwright lifted its price target to US$20 from US$9, citing FY26 total revenue guidance of US$410m to US$420m tied to U.S. demand for Amtagvi and Proleukin, while Wells Fargo moved to US$18 from US$14 and Goldman Sachs pointed to an inflection in the Amtagvi launch and easing logistical challenges. Barclays flagged durability in second line lung cancer for lifileucel ahead of IOV-LUN-202 data, while UBS, which raised its target to US$7 from US$4 and remains Neutral, noted that a strong Amtagvi quarter and gross margin of 56% came alongside a 74% rally in the stock. The valuation model's future P/E multiple changed from 75.55x to 72.80x and the discount rate moved from 7.47% to 7.50%.
IOVA · Capital · Positive Multiple analysts raised price targets and fair value on stronger Amtagvi launch expectations, margin trends, and revenue guidance.
IOVA · Demand · Positive FY26 revenue guidance tied to U.S. demand for Amtagvi and Proleukin, with an inflection in the Amtagvi launch.
Genmab's Rina-S Shows 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
Genmab A/S announced that its investigational antibody-drug conjugate rinatabart sesutecan, known as Rina-S, achieved a confirmed objective response rate of 45.9% among 109 treated patients with platinum-resistant ovarian cancer in Part C of the Phase 1/2 RAINFOL-01 trial. The results, presented in a Late-Breaking Oral Session at the International Gynecologic Cancer Society Congress 2026 in Montreal, Canada, included five complete responses and a median duration of response of 12.1 months, with 51% of responders still in response at one year. The study also reported a median progression-free survival of 9.5 months, and antitumor activity was observed regardless of folate receptor alpha expression levels, including in patients with low expression and non-expressors, and regardless of prior treatment with mirvetuximab. More than half of patients, 53%, had received three or four prior lines of therapy, all had received prior bevacizumab and taxane therapy, 49.5% had received a prior PARP inhibitor, and 33% had received prior mirvetuximab soravtansine. The most common treatment-emergent adverse events were fatigue at 57.8% and low-grade gastrointestinal events including nausea at 67.9%, while serious adverse events were reported in approximately one-third of participants and treatment discontinuation due to adverse events occurred in 5.5%. Rina-S is being evaluated across four Phase 3 trials in platinum-resistant ovarian cancer, endometrial cancer, platinum-sensitive ovarian cancer maintenance, and second-line platinum-sensitive ovarian cancer, plus additional Phase 1/2 and Phase 2 studies.
Johnson & Johnson Reports Sustained Phase 3 Skin Clearance for ICOTYDE in Plaque Psoriasis
Johnson & Johnson reported new Phase 3 results for its oral peptide ICOTYDE in plaque psoriasis at the 2026 EADV Congress, showing sustained skin clearance and improvement across multiple high-impact psoriasis sites, including in adolescent patients. Long-term data from the ICONIC-TOTAL study showed sustained skin clearance through Week 112 at high-impact sites such as the scalp, genital area, hands, feet and nails. The oral IL-23 inhibitor remains in clinical studies for other major inflammatory diseases beyond plaque psoriasis, including psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE is already approved in the U.S., Europe, Japan and China, and the key test ahead is how the evidence translates into prescribing and reimbursement decisions in those markets. Johnson & Johnson is a global healthcare group that develops prescription drugs, medical devices and consumer health products.
Tecan Group Fair Value Estimate Raised to CHF 195.73 on Analyst Target Increases
Analysts lifted their fair value estimate for Tecan Group from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Berenberg sits at the top of the range with a CHF 240 price target and a Buy rating, while Deutsche Bank raised its target in several steps from CHF 138 to CHF 151, then CHF 176, and most recently CHF 198, maintaining a Hold rating. Morgan Stanley moved its target from CHF 142 to CHF 160 and then to CHF 178 while keeping an Equal Weight stance, and Oddo BHF downgraded the stock to Neutral from Outperform with a CHF 192 target. The revised fair value reflects revenue growth assumptions of 5.53%, down from 5.56%, a net profit margin of 9.57% versus 9.70%, a future P/E of 27.00x versus 23.49x, and a discount rate of 4.90% versus 4.82%.
Agenus Reports 48% Three-Year Survival for BOT+BAL in Recurrent Ovarian Cancer
Agenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial, showing an estimated 48% three-year overall survival for botensilimab plus balstilimab in recurrent ovarian cancer. The estimate was unchanged from two years, with median overall survival of 14.8 months, a 23% objective response rate among 35 evaluable patients, and a median duration of response of 9.7 months. At last follow-up, 25% of the 44 patients who received at least one dose, 11 in total, were alive and off all therapy. The heavily pretreated population had received a median of four prior lines of therapy, 77% had received bevacizumab and 57% a PARP inhibitor, and nearly three-quarters had platinum-resistant or refractory disease; estimated three-year survival was 47% in that subgroup and 61% in the 17 patients whose disease had progressed on a PARP inhibitor. The data were presented by Rebecca L. Porter of Dana-Farber Cancer Institute at the 2026 International Gynecologic Cancer Society Annual Global Meeting in Montréal, and Agenus said no new safety signals or treatment-related deaths were reported.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Technology
Biotech & Genomic Medicine › Immuno-Oncology / Checkpoint ▲Technology
AGEN · Technology · Positive Agenus reported positive three-year follow-up data for botensilimab plus balstilimab in recurrent ovarian cancer, with 48% three-year overall survival and no new safety signals.
HSBC Upgrades Target, Citi Downgrades Moderna in Week of Analyst Calls
Wall Street analysts issued a slew of rating changes this week, led by HSBC's upgrade of Target to Buy from Hold with a price target raised to $190 from $125, citing a turnaround "gaining momentum." Citi downgraded Moderna to Sell from Neutral, calling the valuation "unjustifiable" after the biotech rallied more than 222% since a Phase 3 win for its personalized cancer shot intismeran autogene, and cut its price target to $60 from $80. Deutsche Bank downgraded PepsiCo to Hold from Buy, while Goldman Sachs upgraded Occidental Petroleum to Buy from Neutral with a $69 price target, up from $63, and double-downgraded Tourmaline Oil to Sell from Buy with a C$49 target, cut from C$59. Wells Fargo upgraded Consolidated Edison to Overweight from Equal Weight with a $118 target and BP to Overweight from Equal Weight with a $57 target, while downgrading ExxonMobil to Equal Weight from Overweight with an unchanged $182 target. Morgan Stanley reinstated Nvidia as its top pick in the semiconductor space.
Amneal Pharmaceuticals Fair Value Estimate Raised to US$22.71 on Analyst Backing for New Launches
Analysts have lifted their fair value estimate for Amneal Pharmaceuticals to about US$22.71 per share from US$22.00, with price targets from UBS, JPMorgan, Oppenheimer, Barclays and Leerink clustering in the US$20 to US$27 range. UBS points to Amneal's Q2 performance, updated outlook and upcoming biosimilar and generic launches as support for its raised targets in the mid US$20s, while Oppenheimer calls the company a fundamental inflection, citing differentiated launches, the Kashiv acquisition and a vertically integrated biosimilars platform targeting US$1b to US$1.3b of revenue by 2030. Leerink and JPMorgan highlight Affordable Medicines, biosimilars and the Crexont and lanreotide franchises as growth contributors, and Barclays flags the pending gLanreotide approval as a potential clearing event behind its raised US$20 price target. In the updated models, the long-term revenue growth assumption eased to about 9.10% from about 9.60%, the projected net profit margin edged up to about 9.98% from about 9.85%, and the assumed future P/E multiple rose to about 23.2x from about 22.4x, while the discount rate held at about 7.24%.
GRAIL's Galleri Wins Favorable FDA Panel Vote After Strong PATHFINDER 2 Data
GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.
Medtronic Raises Fiscal 2027 Guidance as Revenue Jumps 13.7%
Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.
BillionToOne Fair Value Rises to US$128.57 as Analysts Weigh Reimbursement Risk
BillionToOne's Fair Value estimate has been raised to US$128.57 from US$122.14 in the Simply Wall St framework, as analysts weigh the company's sequencing technology against new reimbursement concerns. Guggenheim lifted its price target on the diagnostics company to US$128 from US$125 ahead of Q3 reporting, while Canaccord initiated coverage with a US$120 target, citing BillionToOne's single molecule next generation sequencing and quantitative counting template technologies as difficult for peers to copy. On the bearish side, Jefferies flagged that the preliminary 2027 CMS clinical laboratory fee schedule points to cuts of up to 15% annually through 2029 for various tests, and noted BillionToOne could see reimbursement pressure on its fetal antigen test, with noninvasive prenatal testing described in the CMS proposal as a more vulnerable application. The framework's revenue growth assumption was trimmed to 26.52% from 28.21%, while profit margin edged up to 15.84% from 15.58%, the future P/E fell to 64.33x from 72.21x, and the discount rate rose to 7.236% from 7.108%.
Biotech & Genomic Medicine › Diagnostics & Precision Testing Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Regulation
Biotech & Genomic Medicine › Life-Science Tools & Sequencing Regulation
BLLN · Capital · Neutral Fair value raised to US$128.57 and Guggenheim/Canaccord price targets lifted on its sequencing technology, but Jefferies flags up to 15% annual CMS reimbursement cuts pressuring its fetal antigen test.
BLLN · Regulation · Negative Preliminary 2027 CMS clinical laboratory fee schedule points to cuts of up to 15% annually through 2029, creating reimbursement pressure on BillionToOne's tests.
Myriad Genetics Jumps 5% After Craig-Hallum Raises Price Target to $8
Myriad Genetics shares jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, according to StreetInsider. The higher price target reflects an increased valuation estimate for the genetic testing company. The move comes after a volatile stretch for the stock, which has seen 44 moves greater than 5% over the last year. Two months ago, Myriad Genetics dropped 46.1% after reporting disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast, with revenue of $190.7 million, down 10.5% year-over-year, and an adjusted loss per share of $0.25. The company also slashed its full-year revenue guidance to a midpoint of $780 million, a decrease of over 10% from its previous forecast. Myriad Genetics is down 30.5% since the beginning of the year, and at $4.27 per share, it is trading 47.9% below its 52-week high of $8.18 from November 2025.
Merck Reports Positive Phase 2b Tulisokibart Results in Hidradenitis Suppurativa
Merck reported positive Phase 2b results for tulisokibart in moderate to severe hidradenitis suppurativa on 1 October 2026. The investigational anti TL1A monoclonal antibody met its Phase 2b efficacy goals in patients with this chronic inflammatory skin condition, and Merck stated that the data support advancing the program into Phase 3 trials in hidradenitis suppurativa. The company said the readout backs the idea that tulisokibart can anchor a new immunology franchise rather than patch a niche condition, helping Merck argue it is building multiple disease-area pillars next to oncology, in contrast to peers like AbbVie and Johnson & Johnson that already lean heavily on immunology blocks. The bear case is that one successful readout does not erase execution risk across the rest of the late stage portfolio, especially with analysts already flagging profit margin pressure and safety questions on assets such as remigromig. Merck is a global healthcare group headquartered in GB that develops medicines across multiple disease areas.
NeuroSense Regains Nasdaq Bid Price Compliance, Will Appeal MVLS Delisting
NeuroSense Therapeutics said it received a letter from Nasdaq's Listing Qualifications Department on October 1, 2026, stating the company has not regained compliance with Listing Rule 5550(b)(2), which requires a minimum market value of listed securities of $35 million for continued listing on the Nasdaq Capital Market. The company intends to appeal the Staff Determination by timely requesting a hearing before the Nasdaq Hearings Panel and to seek additional time to regain compliance with the MVLS Requirement, which is the only continued listing criterion identified in the determination. Nasdaq had notified NeuroSense on April 2, 2026, that its MVLS had been below $35 million for 30 consecutive trading days, giving it until September 29, 2026, to regain compliance; because it did not, its ordinary shares and warrants face delisting unless it appeals. A timely hearing request stays the suspension of the company's securities and the filing of a Form 25-NSE with the SEC pending the Panel's decision, and the Panel has discretion to grant an exception of up to 180 days from the date of the Staff Determination. Separately, NeuroSense said Nasdaq confirmed it regained compliance with Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement, after its 1-for-20 reverse share split kept the closing bid price at $1.00 or greater for 10 consecutive business days from September 15 through September 28, 2026, closing that matter. Chief Executive Officer Alon Ben-Noon said regaining bid price compliance is an important step and that the company remains focused on advancing PrimeC in ALS, including preparations for its Phase 3 PARAGON trial and a planned New Drug Submission to Health Canada.
Biotech & Genomic Medicine › Neuroscience & Neurodegenerative ▼Regulation
NRSN · Regulation · Negative Nasdaq determined NeuroSense failed to regain the $35M minimum market value of listed securities requirement, leaving its shares and warrants facing delisting unless its appeal succeeds.
Biogen litifilimab shows durable lupus skin clearance at 52 weeks
Biogen's litifilimab produced clear or almost clear skin and reduced disease activity in cutaneous lupus erythematosus patients after one year of treatment, according to long-term phase 2 data. In the phase 2 portion of the AMETHYST Phase 2/3 study, 27.2% of patients on litifilimab met the clinical endpoint of clear or almost clear skin at week 52, as measured by a Cutaneous Lupus Activity Investigators' Global Assessment Revised erythema score of 0 or 1, up from 19% at week 24. The Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-70, a measure of disease activity reduction, also improved with longer treatment, reaching 28.8% at week 52 compared with 21.7% at week 24. Biogen noted that patients who began the study on placebo and switched to litifilimab mid-study saw improvements as early as four weeks after starting active treatment, and by week 52, 33.7% of the crossover participants had clear or almost clear skin.
FluoGuide Enters Collaboration with Leica Microsystems on Brain Tumor Surgery
FluoGuide A/S announced a collaboration with Leica Microsystems, a Danaher company and world leading medical technology company, to advance precision surgery for brain tumors. The agreement is a milestone in brain tumor surgery development, aiming to optimize the use of imaging systems and FluoGuide's lead product FG001 to enable better treatment for patients with high-grade glioma cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Leica's technology platform. The agreement has no initial payment, is non-exclusive, and its terms are not disclosed; it will not have an impact on FluoGuide's financial results in 2026. FG001 has received both Fast Track and Orphan Drug Designations from the FDA, supporting its development in high-grade glioma in the US, and FluoGuide is listed on Nasdaq First North Sweden under the ticker FLUO.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics Technology
FluoGuide A/S · Technology · Positive FluoGuide's FG001 enters a collaboration with Leica Microsystems to advance precision surgery for high-grade glioma.
Leica Microsystems · Technology · Positive Leica Microsystems collaborates with FluoGuide to optimize its imaging systems with FG001 for brain tumor surgery.
DHR · Technology · Positive Danaher's Leica Microsystems unit enters a collaboration to advance precision brain tumor surgery using FluoGuide's FG001 with its imaging platform.
